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Summary
Objective An increased rate of fractures has been reported in
patients with Turner syndrome (TS). We aimed to assess bone
geometry and volumetric bone mineral density (vBMD) at the
radius in girls with TS and to evaluate the relationships between
bone parameters and fracture history.
Methods and design Sixty-seven girls with TS aged 6–19 years
treated currently or in the past with growth hormone (GH) and/or
oestrogens were examined using peripheral quantitative computed
tomography. Results were compared to reference data.
Results Cortical area and cortical thickness were low in all age
groups (all P < 0Æ001). Height-adjusted total bone area at the
diaphysis was increased in prepubertal and postpubertal girls
(mean Z-score 1Æ0, P < 0Æ05 for both) and normal in the pubertal
group (mean Z-score 0Æ1). Cortical vBMD was decreased (mean
age-specific Z-scores )2Æ0, )1Æ6 and )1Æ0 for prepubertal, pubertal
and postpubertal groups, respectively, P < 0Æ01 for all groups).
Height- , age- and cortical thickness-adjusted cortical vBMD was
positively correlated to the duration of GH therapy (P = 0Æ012)
and to oestrogen administration (P = 0Æ047). Girls with a history
of fractures had lower total vBMD at the metaphysis compared to
nonfractured TS girls (mean Z-scores )1Æ7 vs )0Æ9, P = 0Æ04).
Conclusions There is a cortical bone deficit in girls with TS char-
acterized by low cortical area, thin cortex and probably decreased
cortical vBMD. Early commencement of GH therapy, as well as
oestrogen replacement, is associated with higher cortical vBMD.
Further studies should investigate the potential causality of this
relation.
(Received 3 September 2010; returned for revision 15 October
2010; finally revised 2 December 2010; accepted 3 December
2010)
Introduction
A significant increase in fracture rate has been described in females
with Turner syndrome compared to the general population.1,2
The aetiology of increased bone fragility in Turner syndrome (TS)
has not yet been completely elucidated. Traditionally, it is attrib-
uted to oestrogen insufficiency because of hypogonadism and/or
to a primary bone defect linked to sex chromosome haploinsuffi-
ciency.
Several studies using dual-energy x-ray absorptiometry (DXA)
have reported decreased bone mineral density (BMD) in females
with TS, in whom a variable decrease in lumbar spine BMD was
observed with mean Z-scores ranging from )2Æ3 to )0Æ8.3–5
However, planar methods – such as X-ray absorptiometry – are
inherently limited in that they ignore the third bone dimension.
People with a short stature, such as patients with TS, are
assigned artificially decreased areal bone mineral density (aBMD)
on planar methods.6 Indeed, substantially better lumbar spine
BMD values are obtained when appropriate adjustments are
made for body height or bone size. By increasing the mean
Z-scores by 0Æ3–1Æ8, such a size adjustment led to a significant
reduction in the number of TS patients diagnosed with osteopo-
rosis.3–5 Compared to planar densitometry, quantitative volumet-
ric techniques such as the peripheral quantitative computed
tomography (pQCT) have several advantages for the study of
bone: they are not affected by bone size, they distinguish trabec-
ular from cortical volumetric BMD (vBMD), and they assess
bone geometry. Along with low radiation dose, pQCT is thus a
useful tool for analyses of bone properties in short and dispro-
portional children.
To our best knowledge, only three studies have applied volumet-
ric techniques on patients with TS, all performed on patient groups
of a rather limited size. Nanao et al. reported decreased lumbar
spine vBMD in 21 girls with TS using QCT.7 Bechtold et al.8
reported decreased total vBMD in 21 young adults with TS using
pQCT at the radius, and Holroyd et al.9 found decreased cortical
vBMD, but normal trabecular vBMD in 22 TS girls by the same
method. Given the small sample sizes in the former studies, the lack
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of knowledge regarding the effect of growth hormone (GH) and
oestrogens on bone variables, and still missing data regarding the
indicators of bone strength, we set out to elucidate this topic in a
larger sample of patients with TS. Moreover, we report for the first
time height-specific Z-scores for volumetric bone parameters in
TS.
The aims of our study were as follows: (i) to assess bone geome-
try and volumetric BMD at the radius in girls with TS comparing
the parameters between prepubertal, pubertal and postpubertal
groups; (ii) to investigate the impact of the duration of growth hor-
mone therapy and oestrogen replacement on their bone; and (iii)
to compare densitometric indicators of bone strength between girls
with history of fractures and nonfractured girls.
Patients andmethods
Subjects
We examined 67 girls with TS aged 6–19Æ4 years, selected from 82
girls with TS that were regularly followed up at the University Hos-
pital Motol in Prague, Czech Republic. The reasons for excluding
the remaining 15/82 girls were as follows: coeliac disease (5),
inflammatory bowel disease (2), poor cooperation during densi-
tometry (3) and patient refusal (5). Using Tanner’s classification of
puberty, all girls presenting with breast stage 1 were considered pre-
pubertal, the girls with breast stage 2 or more were considered
pubertal. The end of the puberty was defined by cessation of body
growth, i.e. by the time GH therapy has been stopped for at least
6 month. All postpubertal girls had breast Tanner stage 4 or 5. At
the time of densitometric testing, 22 girls were prepubertal, 25 girls
were pubertal, and 20 girls were postpubertal (Table 1). Their kary-
otypes were either 45,X (24/67, 36%), various forms of mosaicism
(35/67, 52%) or a structurally abnormal X chromosome (8/67,
12%).
The study was approved by the Ethics Committee of the Univer-
sity Hospital Motol, Prague. Informed consent was obtained from
all participants and/or their guardians.
Hormone therapy
At the time of bone densitometry, all prepubertal and pubertal
patients with TS were treated with recombinant human GH while
postpubertal girls had been off the therapy for a median 1Æ5 years
(range 0Æ6–3Æ7). GH starting dose of 50 lg/kg/day was adjusted
during therapy according to clinical response.10 Median age at start
of GH therapy was 7Æ0 years (range 2Æ4–15Æ4), median duration of
GH administration was 5Æ8 years (range 0Æ0–11Æ9).
Oestrogen replacement was given to 20/25 patients from the
pubertal group and to 19/20 patients from the postpubertal group.
The remaining 5/25 pubertal patients entered puberty spontane-
ously and 1/20 postpubertal patient underwent spontaneous pub-
erty. Oestrogen replacement was started at the median age of
12Æ8 years (range 10Æ4–16Æ3), with a starting dose of 5 lg/kg/day
of 17-b-estradiol given for 12–18 months.11,12 Afterwards, a dose of
10 lg/kg/day was administered for another 12–18 months, followed
by an increase to 20 lg/kg/day. After a mean period of 3 months, the
same dose of estradiol was continued from day 1 to 21, with 5 mg of
medroxyprogesterone per day added from day 15 to 21. No other
medication known to influence bone metabolism was given except
for thyroxine substitution for autoimmune thyroiditis in 15 girls,
which had been long-term euthyroid before the densitometry.
Measurement methods
On the day of bone densitometry, body height was measured by
stadiometer to nearest 1 mm and weight was measured by elec-
tronic scale to nearest 100 g. Height, weight and BMI Z-scores were
calculated using national reference data.13
Peripheral quantitative CT (XCT 2000; Stratec Medizintechnik,
Pforzheim, Germany) was used for bone assessment at the non-
dominant radius. A single tomographic 2 mm-thick slice was taken
at the distance corresponding to 4% and 65% forearm length mea-
sured from processus styloideus ulnae to the olecranon. Image pro-
cessing and the calculation of numerical values were carried out
using the integrated xct software version 6.00 B. At the distal
Table 1. Clinical characteristics of the study group at the time of peripheral quantitative computed tomography measurement
Prepubertal girls
(N = 22)
Pubertal girls
(N = 25)
Postpubertal girls
(N = 20)
Group difference
(P-value)
Age (year) 10Æ3 (2Æ2) 14Æ3 (1Æ7) 17Æ4 (1Æ2) <0Æ001
Height (cm) 132Æ8 (12Æ9) 149Æ8 (6Æ0) 157Æ5 (2Æ9) <0Æ001
Height Z-score )1Æ6 (1Æ0)*** )2Æ0 (0Æ6)*** )1Æ5 (0Æ5)*** 0Æ107
Weight (kg) 33Æ3 (10Æ4) 47Æ3 (7Æ9) 61Æ4 (9Æ2) <0Æ001
Weight Z-score )0Æ5 (1Æ0)* )0Æ6 (0Æ9)** 0Æ3 (1Æ2) 0Æ009
BMI (kg/m2) 18Æ4 (3Æ0) 21Æ0 (2Æ7) 24Æ8 (3Æ6) <0Æ001
BMI Z-score 0Æ4 (0Æ9)* 0Æ5 (0Æ9)* 1Æ1 (1Æ0)*** 0Æ034
Duration of growth hormone therapy (year) 4Æ2 (3Æ2) 5Æ8 (3Æ3) 7Æ7 (2Æ1) 0Æ001
Duration of oestrogen therapy (year) NA 1Æ6 (0Æ7) 4Æ2 (1Æ2) <0Æ001
Spontaneous puberty (number of patients) NA 5 1 NA
Mean (SD) values are shown. Comparison to healthy population was tested by one-sample t-test, sign test was used instead, whenever normality was rejected
by Shapiro–Wilk test: *P < 0Æ05, **P < 0Æ01, ***P < 0Æ001. One-way anova was used to compare between the three groups, P-value shows the intergroup
significances.
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radius (4% site), bone mineral content (BMC), total and trabecular
vBMD, total bone cross-sectional area (total area) and polar
strength-strain index (SSI) were assessed. Strength/weight index
was calculated as proposed by Rauch et al.14 At the proximal radius
(65% site), BMC, total and cortical vBMD, total area, cortical
cross-sectional area (cortical area), polar SSI and muscle area (MA)
were assessed. SSI was determined by using a segmentation thresh-
old of 480 mg/cm3. Total area and cortical area were determined
by detecting the outer and inner cortical bone contour at a thresh-
old of 710 mg/cm3. Relative cortical area was mathematically
derived by dividing cortical area by total area. Cortical thickness
was computed by integrated software under the assumption of a
circular ring model. BMC divided by muscle area (BMC/MA ratio)
was used to evaluate the muscle–bone unit. Z-scores were
calculated using published reference data created on the related
neighbouring German population15–17 using Cole’s formula18:
Z-score = [Ln(patient’s test result/M)]/S, where Ln is the natural
logarithm, M corresponds to the age- and sex-specific mean value
and S is the age- and sex-specific coefficient of variation. For
diaphyseal BMC, total area, cortical area, SSI and muscle
area, height-specific Z-scores were also calculated using the same
literature.
According to the recommendation of the International Society
for Clinical Densitometry, 19 the precision error (expressed as root
mean square standard deviation, RMS SD) was calculated from
three consecutive measurements with repositioning in fifteen
healthy young adult volunteers (mean age 25Æ1). Precision errors of
the primary measures were as follows: at the distal radius, BMC
0Æ943 mg/mm, trabecular vBMD 2Æ905 mg/cm3, total vBMD
9Æ353 mg/cm3, total area 9Æ617 mm2 and SSI 10Æ031 mm3; at the
proximal radius, BMC 0Æ745 mg/mm, total vBMD 4Æ947 mg/cm3,
cortical vBMD 4Æ641 mg/mm3, total area 1Æ193 mm2, cortical area
1Æ021 mm2, cortical thickness 0Æ068 mm, SSI 7Æ685 mm3 and mus-
cle area 46Æ313 mm2.
Statistical analysis
All analyses were performed in the statistical computing envi-
ronment R.20 Comparisons with the healthy population were
based on the one-sample t-test or the sign test (Tables 1 and
2). The one-sample t-test was used whenever normality was
suggested by the Shapiro–Wilk test. One-way anova was used
to compare anthropometric and densitometric parameters
between prepubertal, pubertal and postpubertal TS girls (Table 2).
Table 2. Bone parameters shown separately for prepubertal, pubertal and postpubertal Turner syndrome girls
Prepubertal group (N = 22) Pubertal group (N = 25) Postpubertal group (N = 20) Group
difference
(P-value)Value Z-score Value Z-score Value Z-score
Distal radius
BMC (mg/mm) 59Æ1 (15Æ7) )0Æ5 (1Æ2) 74Æ0 (13Æ8) )1Æ2 (1Æ3)*** 96Æ2 (12Æ8) )0Æ6 (0Æ9)* 0Æ070
Total vBMD (mg/cm3) 270Æ5 (34Æ6) )0Æ5 (1Æ1)* 262Æ5 (45Æ0) )1Æ4 (1Æ5)*** 295Æ0 (44Æ7) )1Æ3 (1Æ0)*** 0Æ032
Trabecular vBMD (mg/cm3) 185Æ4 (33Æ7) )0Æ2 (1Æ1) 170Æ0 (29Æ4) )0Æ7 (1Æ1)** 152Æ6 (30Æ8) )1Æ4 (1Æ3)*** 0Æ007
Total area (mm2) 222Æ0 (64Æ3) )0Æ2 (1Æ5) 285Æ2 (52Æ2) 0Æ1 (1Æ1) 329Æ2 (42Æ8) 0Æ7 (0Æ9)** 0Æ059
SSI (mm3) 128Æ9 (43Æ0) – 183Æ0 (64Æ3) – 302Æ0 (65Æ2) – <0Æ001
Strength/weight index (mm3/kg/m) 21Æ5 (6Æ0) – 18Æ0 (6Æ1) – 22Æ2 (6Æ0) – 0Æ047
Proximal radius
BMC (mg/mm) 54Æ1 (10Æ8) )1Æ2 (1Æ0)*** 69Æ1 (10Æ8) )1Æ5 (1Æ2)*** 83Æ6 (14Æ6) )1Æ0 (1Æ2)** 0Æ239
BMC (height adjusted) )0Æ0 (1Æ5) )0Æ3 (1Æ2) )0Æ1 (1Æ1) 0Æ714
Total vBMD (mg/cm3) 510Æ8 (100Æ4) )1Æ5 (1Æ6)*** 652Æ9 (99Æ0) )0Æ6 (1Æ1)* 656Æ8 (106Æ0) )1Æ0 (1Æ5)** 0Æ098
Total vBMD (height adjusted) )0Æ9 (1Æ5)** )0Æ1 (1Æ0) )0Æ5 (1Æ4) 0Æ103
Cortical vBMD (mg/cm3) 936Æ1 (59Æ2) )2Æ0 (1Æ7)*** 1025Æ5 (57Æ2) )1Æ6 (1Æ5)*** 1090Æ6 (37Æ7) )1Æ0 (1Æ2)*** 0Æ102
Total area (mm2) 96Æ6 (32Æ1) 0Æ3 (1Æ6) 92Æ6 (16Æ5) )0Æ9 (1Æ3)** 116Æ9 (34Æ5) )0Æ1 (1Æ9) 0Æ035
Total area (height adjusted) 1Æ0 (1Æ8)* 0Æ1 (1Æ3) 1Æ0 (1Æ8)* 0Æ110
Cortical area (mm2) 38Æ2 (10Æ8) )1Æ3 (1Æ3)*** 53Æ4 (9Æ3) )1Æ4 (1Æ1)*** 62Æ3 (11Æ1) )1Æ2 (1Æ2)*** 0Æ867
Cortical area (height adjusted) )0Æ1 (1Æ2) )0Æ1 (0Æ9) 0Æ1 (0Æ9) 0Æ681
Relative cortical area 0Æ43 (0Æ15) )2Æ7 (3Æ9)** 0Æ59 (0Æ11) )0Æ8 (2Æ0) 0Æ56 (0Æ12) )2Æ1 (3Æ0)** 0Æ100
Cortical thickness (mm) 1Æ3 (0Æ3) )0Æ8 (0Æ7)*** 1Æ8 (0Æ3) )0Æ7 (0Æ4)*** 1Æ8 (0Æ3) )0Æ9 (0Æ5)*** 0Æ465
SSI (mm3) 136Æ5 (47Æ3) )0Æ7 (1Æ2)* 175Æ0 (39Æ4) )1Æ3 (1Æ2)*** 239Æ1 (64Æ4) )0Æ6 (1Æ3) 0Æ106
SSI (height adjusted) 1Æ0 (1Æ2)*** 0Æ5 (1Æ2) 1Æ2 (1Æ3)*** 0Æ105
Muscle area (mm2) 1886Æ2 (438Æ9) )0Æ9 (1Æ2)** 2240Æ4 (292Æ1) )1Æ3 (1Æ1)*** 2439Æ2 (277Æ6) )1Æ3 (1Æ0)*** 0Æ400
Muscle area (height adjusted) 1Æ5 (2Æ3)** 0Æ6 (2Æ4) 0Æ4 (2Æ0) 0Æ257
BMC/MA 2Æ9 (0Æ4) )0Æ5 (1Æ0)* 3Æ1 (0Æ4) )0Æ3 (1Æ1) 3Æ4 (0Æ5) 0Æ2 (1Æ2) 0Æ175
Values are expressed as mean (SD). Age-related values are shown if not stated otherwise. Comparison to healthy population was tested by one-sample t-test,
sign test was used instead, whenever normality was rejected by Shapiro–Wilk test: *P < 0Æ05, **P < 0Æ01, ***P < 0Æ001. One-way anova was used to compare
subgroups, intergroup significances in Z-scores (if available) are expressed as P-values. SSI, strength-strain index. BMC/MA, bone mineral content/muscle
area.
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Multivariate and univariate multiple regression analysis was used to
assess the dependency of logarithmically transformed bone mea-
sures on the duration of growth hormone and oestrogen therapy
after adjustment for age, age squared and height Z-score (Fig. 3).
The same linear regression model was used for all bone measures
except for cortical vBMD, where cortical thickness Z-score was also
included. The residuals in the multiple regression models were
tested for normality using Shapiro–Wilk test (normality was
rejected only for diaphyseal total area, but the model without the
outlier was very similar).
Results
Differences between prepubertal, pubertal and
postpubertal girls with TS
Densitometric parameters expressed as mean values and mean age-
and height-specific Z-scores for the prepubertal, pubertal and post-
pubertal groups are summarized in Table 2.
At the distal radius (4% site), age-adjusted total area was normal
in prepubertal and pubertal girls (P = 0Æ605 and P = 0Æ761), but
enlarged in the postpubertal group (P = 0Æ003). A significant dif-
ference between the three groups was found for trabecular vBMD
(P = 0Æ007), which was normal in prepubertal girls (P = 0Æ502),
but decreased during and after puberty (P = 0Æ007 and P < 0Æ001;
Fig. 1).
At the proximal radius (65% site), age-adjusted total area was
normal in the prepubertal and postpubertal groups (P = 0Æ384 and
P = 0Æ826), but decreased in pubertal girls (P = 0Æ002; Fig. 2). In
contrast, substantially higher values were gained when height-spe-
cific Z-scores were calculated, showing enlarged total area in prepu-
bertal and postpubertal girls (P = 0Æ024 and P = 0Æ022) and
comparable total area in pubertal group (P = 0Æ695; Table 2). Sim-
ilarly, the results for cortical area, SSI, muscle area and also BMC
were substantially influenced by the selected method of compari-
son (age- or height-adjustment). For all these variables, consider-
ably better results were observed after adjustment for body height
(Table 2). Mean age-specific Z-scores for cortical vBMD and corti-
cal thickness were low in all age groups (P < 0Æ001 for all; Table 2,
Figs 1 and 2). Relative cortical area was decreased in prepubertal
and postpubertal groups (P = 0Æ004 and P = 0Æ006), but normal in
pubertal girls (P = 0Æ052; Table 2, Fig. 2).
Predictors of bone parameters in TS
The effect of GH and oestrogens on bone variables in TS was statis-
tically significant (multivariate multiple regression model, Pillai-
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Fig. 1 Individual values for cortical (a) and trabecular (b) volumetric bone
mineral density vs age at the radius in Turner syndrome girls. Open circles
represent prepubertal, daggers pubertal and triangles postpubertal girls.
Nomogram represents mean ± 2SD of healthy population.
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Fig. 2 Individual values for total area (a), cortical
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ness (d) vs age at the proximal radius in Turner
syndrome girls. Open circles represent prepubertal,
daggers pubertal and triangles postpubertal girls.
Nomogram represents mean ± 2SD of healthy
population.
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Bartlett test, P-value 0Æ0073). The size of the effect on each of the
bone variables was assessed using univariate multiple regression
models.
At the distal radius, an increase in duration of GH therapy by
1 year corresponded to 2Æ0% (95% CI 0Æ38–3Æ6%) gain in BMC
and to 1Æ8% (95% CI 0Æ20–3Æ4%) gain in total area (Fig. 3). We did
not find any significant association between either growth hor-
mone or oestrogens and trabecular vBMD.
At the proximal radius, an increase in duration of GH therapy by
1 year (Fig. 3) corresponded to 0Æ5% (95% CI 0Æ01–0Æ98%)
increase in cortical vBMD. Because there was a significant
correlation between cortical vBMD and cortical thickness in our
patients (r = 0Æ86), a correlation caused by the partial volume
effect,21 we added cortical thickness Z-score in the multiple regres-
sion model for cortical vBMD to account for possible bias. After
this adjustment, an increment in duration of GH or oestrogen ther-
apy by 1 year was associated with 0Æ40% (95% CI 0Æ090–0Æ70%)
and 1Æ0% (95% CI 0Æ020–2Æ0%) respective gain in cortical vBMD
(Fig. 3).
A 1-year increase in duration of oestrogen therapy corresponded
to increments in diaphyseal BMC of 6Æ2% (95% CI 1Æ5–10Æ9%), in
BMC/MA ratio of 4Æ9% (95% CI 0Æ70–9Æ2%) and in diaphyseal SSI
of 9Æ0% (95% CI 1Æ7–16Æ3%).
History of fractures and bone parameters in TS
A positive fracture history was reported in 14/67 (21%) girls with
TS. The total number of reported fractures was 26 (13 wrist frac-
tures, 10 forearm fractures, 1 shank fracture, 1 finger fracture and 1
nontraumatic vertebral fracture). Three girls fractured twice, 1 girl
fractured three times and two girls had experienced four lifetime
fractures.
TS girls with positive history of fractures had significantly lower
total vBMD at the distal radius compared to nonfractured patients
(Table 3). No significant changes were found between the two
groups in any other of the bone parameters, GH or oestrogen treat-
ment duration, or age at treatment start. Finally, we did not find
any differences in the analysed bone and muscle parameters
between the two groups to be influenced by the karyotype.
Discussion
In this study, we characterized bone geometry and volumetric
BMD at the radius in prepubertal, pubertal and postpubertal girls
with Turner syndrome using peripheral QCT. We found that (i)
cortical area and cortical thickness at the diaphysis of the radius are
low in all age groups, while total area is normal except for a
Fig. 3 Changes in bone parameters (dependent variables) predicted by
1-year increment of growth hormone therapy and oestrogen replacement
duration (expressed as exponentials of beta coefficients with 95% CI).
Multiple regression analysis with correction for age, age squared and height
Z-score. For cortical volumetric bone mineral density, cortical thickness
Z-score was also included in the model (indicated by asterisk). Values of
bone parameters were logarithmically transformed.
Table 3. Differences in clinical and bone characteristics between nonfractured and fractured girls with Turner syndrome
Nonfractured girls (N = 53) Fractured girls (N = 14)
Group difference
(P-value)Value Z-score Value Z-score
Anthropometry
Age (year) 13Æ9 (3Æ3) 14Æ0 (3Æ7) 0Æ901
Height (cm) 146Æ4 (12Æ4) 147Æ0 (16Æ0) 0Æ889
Distal radius
BMC (mg/mm) 75Æ5 (19Æ7) )0Æ7 (1Æ2) 76Æ6 (23Æ5) )0Æ9 (1Æ3) 0Æ740
Total vBMD (mg/cm3) 279Æ4 (42Æ5) )0Æ9 (1Æ3) 257Æ5 (43Æ7) )1Æ7 (1Æ1) 0Æ039
Total area (mm2) 272Æ0 (63Æ8) 0Æ0 (1Æ3) 298Æ9 (83Æ0) 0Æ7 (1Æ1) 0Æ071
Trabecular vBMD (mg/cm3) 171Æ6 (33Æ7) )0Æ7 (1Æ3) 163Æ0 (32Æ9) )0Æ9 (1Æ1) 0Æ434
SSI (mm3) 203Æ3 (91Æ4) – 191Æ2 (91Æ6) – 0Æ662
Strength/weight index (mm3/kg/m) 20Æ5 (5Æ9) – 20Æ1 (7Æ6) – 0Æ824
Values are expressed as mean (SD). Two-sample t-test was used to compare subgroups, intergroup significances in Z-scores (if available) are expressed as
P-values. vBMD, volumetric bone mineral density; BMC, bone mineral content; SSI, strength-strain index.
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decrease in the pubertal group. However, after adjustment for body
height, total area is generally enlarged (except in the pubertal group
where it is normal), while cortical area is normal in all age groups;
(ii) cortical vBMD is decreased in all age groups; (iii) trabecular
vBMD is normal in prepubertal girls but deteriorates during and
after puberty; (iv) the duration of GH and oestrogen therapy corre-
lates positively with cortical vBMD; and (v) total vBMD at the
metaphysis is significantly lower in patients with a positive fracture
history.
Bone geometry of the radius
Bone geometry is strongly influenced by body height. Therefore,
dimensional scaling is mandatory when assessing bone variables in
children with short stature, such as patients with TS. We found that
the radius is enlarged in prepubertal and postpubertal girls with TS
at the diaphyseal cross-section after an adjustment for height. An
enlargement of bone cross-section leading to greater resistance to
bending and torsion has been described as a physiological adapta-
tion of the bone to mechanical loading mediated by skeletal muscle
contraction.22,23 Therefore, an enlarged total area in subjects with a
disrupted cortical bone could be interpreted as a result of an
adjustment of bones to mechanical loading, aiming to decrease
bone fragility. In accordance with this concept, we found a high
height-adjusted proximal radius SSI in prepubertal and postpuber-
tal groups. Different results seen in the pubertal group could be
explained by the fact that we always compared girls of a different
pubertal status, using either height- or age-specific Z-scores. Puber-
tal girls with TS are hyperestrinic compared to height-matched (i.e.
prepubertal) healthy peers, but hypoestrinic compared to age-
matched healthy girls. Wang et al.24 found out recently that the
serum estradiol level correlates negatively with endocortical cir-
cumference at the tibial shaft in healthy pubertal girls, but later on
after menarche, a positive correlation was found with total bone
area. Thus, lower oestrogen doses administered to our pubertal TS
girls could have acted primarily on the endocortical bone surface,
causing an increase in the cortical thickness and the relative cortical
area, whereas higher doses given to postpubertal TS girls could
have promoted periosteal expansion, causing enlargement of
the bone.
Cortical vBMD and cortical thickness
The low cortical vBMD observed in our TS girls supports the
hypothesis of a selective cortical bone deficit in TS, as previously
postulated in the literature.9,25 Bakalov et al.25 found decreased
aBMD at the distal third of radius (a site with prevalent cortical
bone) using DXA in adult patients with TS and Holroyd et al.9
found decreased cortical vBMD at the radius using pQCT in post-
pubertal TS girls. However, the assessment of cortical vBMD val-
ues is biased by cortical thickness. This is because of a partial
volume effect,21 which is bound to result in falsely low values –
especially in subjects with thin cortices, including girls with TS.
The thinner the cortex, the higher the proportion of voxels com-
prising soft tissues at the cortical bone margin (periosteum and
endosteum). Thus, it seems that the low cortical vBMD readings
in TS (described here and in literature) correspond at least partly
to an effect of thin cortices. Hence, in an attempt to adjust for the
partial volume effect, a correction formula was used devised by
Rittweger et al.26 When this correction algorithm was applied,
cortical vBMD was found to be elevated above normal (mean
Z-scores 1Æ1, 0Æ7 and 1Æ4, P < 0Æ01 for all). A validation of the algo-
rithm using synthetic specimens26 has shown that it slightly
under-corrects the cortical vBMD, rather than over-correcting it.
Therefore, it is unlikely that the application of this correction
algorithm is responsible for the elevated cortical vBMD values
found in TS children. On the other hand, one also has to consider
beam hardening, which is bound to show a lower cortical density
in larger bones, and which could thus explain the effect. In conclu-
sion, the question of whether cortical vBMD is reduced in TS chil-
dren remains yet open. It is, however, important to realize that
such a difference would be relatively small (78Æ13, 52Æ01 and
29Æ08 mg/cm3 for prepubertal, pubertal and postpubertal group,
respectively) and that the main effects of TS on bone are linked to
bone geometry, and not tissue density.
Trabecular vBMD
Oestrogens have strong effects upon the trabecular network. Our
finding of decreased trabecular vBMD during and after puberty
could therefore be expected in hypogonadal TS girls. Our observa-
tion generally agrees with studies showing normal size-adjusted
lumbar spine areal BMD before puberty but a lack of adequate
pubertal bone mass acquisition in TS girls.27,28 Similar results were
observed in hypogonadal patients assessed by QCT.7 However, the
only two previously published studies performed on postpubertal
TS girls using pQCT showed normal trabecular vBMD at the
radius.8,9 We have no clear explanation for this contradiction. We
may only speculate about the type and/or dosage of oestrogens
used that was different in study by Bechtold et al. (estradiol valerate
2 mg/day) and our study (17-b-estradiol 1Æ2 mg/day), and a differ-
ent age at densitometry (19Æ5 ± 2Æ3 vs 17Æ2 ± 1Æ3 years in our post-
pubertal girls), but further research is needed to provide more
insight into this issue.
GH therapy and bone
The impact of GH on bone density is still controversial. There is
no doubt that GH and IGF-1 have an anabolic effect on bone and
muscle, stimulating bone growth in length (by stimulation of the
growth plate) and width (by periosteal expansion mediated mostly
through muscles). Nevertheless, data on the skeletal effects of GH
in TS and other non-GHD subjects are still limited. Whereas GH
therapy was reported to lead to a gain in mid-phalangeal BMD in
pubertal TS patients in a single radiographic absorptiometry
study,29 the DXA studies described an increment in bone area but
not the aBMD at the radius,30 and an increase in muscle mass but
no change in the total body aBMD31 in patients with TS. Our
finding that the duration of the GH therapy is positively corre-
lated with cortical vBMD is consistent with studies published on
patients with acromegaly – these described increased cortical but
not trabecular BMD at different sites, including the radius.32,33
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In addition, a single placebo-controlled study showed a dose-
dependent effect of GH to increase femoral neck and total body
BMC in osteoporotic non-GHD elderly women.34 Moreover, in
experiments on rodents, GH administration to non-GHD rats
lead to increased cortical bone mass and bone strength.35
However, further longitudinal studies are needed to clarify this
point.
Oestrogens and the bone
We found that the duration of oestrogen replacement was posi-
tively correlated with cortical vBMD, BMC, BMC/MA and SSI at
the radial diaphysis. This is in accordance with the results of a sin-
gle placebo-controlled study in TS describing an association
between oestrogen replacement and gain in mid-phalangeal BMD,
i.e. a cortical bone site.36 Our findings support the mechanostat
theory denoting oestrogens as modulators of bone resorption
threshold at the endocortical site. The positive effect of oestrogens
on bone reported in the present study is in accordance with the
finding by Landin-Wilhelmsen et al.1 who described a 19-fold
increase in the fracture risk in untreated women with TS aged >45
compared to the general population.
Bone strength and fractures in TS
An increased rate of fractures has been reported in patients with
TS.1,2 Interestingly, the fracture risk was significantly different from
the general population only at the forearm (relative risk of 1Æ9).2
This finding makes the pQCT a promising method for bone analy-
sis in TS, because the measurement is performed directly at the site
of the increased fracture risk. In this study, we showed for the first
time that girls with TS who underwent at least one fracture in their
life have a lower total vBMD at the distal radius when compared to
the nonfractured subjects. The total vBMD at this site represents
the combined density of the cortical bone envelope and the trabec-
ular bone inside. As there was no difference in the trabecular vBMD
between the two groups, a more pronounced cortical bone deficit
in fractured girls could be responsible for this finding. However,
because of very thin cortices at the metaphysis, we could not fur-
ther verify this hypothesis by assessing cortical bone at the distal
site by pQCT.
The limitation of this study lies in its cross-sectional design. Pro-
spective studies are needed to find out whether correlations of GH
and oestrogens to the densitometric variables observed in this study
reflect a truly causal mechanism, or whether our observations are
because of an action of a yet unknown confounder influencing
bone strength in TS girls.
In conclusion, our study describes differences in bone geometry
and volumetric BMD at the radius in a considerable number of
girls with TS of different pubertal stages. The altered bone geome-
try is probably the result of bone adaptation to mechanical loading
in the presence of a cortical bone deficit, and oestrogens may play a
role in the changes in bone geometry according to the pubertal
stage. Longitudinal data are needed to elucidate the role of the hor-
monal therapy on bone and to find the best predictor for fractures
in patients with TS.
Declaration of interest
No conflicts declared.
Funding
This work was supported by Charles University (GAUK 47609),
Czech Ministry of Health (VZ MZ 64203) and Czech Ministry of
Education (MSMT 21620819).
Disclosure
The authors have nothing to declare.
References
1 Landin-Wilhelmsen, K., Bryman, I., Windh, M. et al. (1999) Oste-
oporosis and fractures in Turner syndrome-importance of growth
promoting and oestrogen therapy. Clinical Endocrinology, 51, 497–
502.
2 Gravholt, C.H., Vestergaard, P., Hermann, A.P. et al. (2003)
Increased fracture rates in Turner’s syndrome: a nationwide ques-
tionnaire survey. Clinical Endocrinology, 59, 89–96.
3 Gravholt, C.H., Lauridsen, A.L., Brixen, K. et al. (2002) Marked
disproportionality in bone size and mineral, and distinct abnor-
malities in bone markers and calcitropic hormones in adult turner
syndrome: a cross-sectional study. Journal of Clinical Endocrinology
&Metabolism, 87, 2798–2808.
4 Bakalov, V.K., Chen, M.L., Baron, J. et al. (2003) Bone mineral
density and fractures in Turner syndrome. The American Journal of
Medicine, 115, 259–264.
5 Lage, A.Z., Brandao, C.A., Mendes, J.R. et al. (2005) High degree of
discordance between three-dimensional and two-dimensional lum-
bar spine bone mineral density in Turner’s syndrome. Journal of
Clinical Densitometry, 8, 461–466.
6 Carter, D.R., Bouxsein, M.L. & Marcus, R. (1992) New approaches
for interpreting projected bone densitometry data. Journal of Bone
and Mineral Research, 7, 137–145.
7 Nanao, K., Tsuchiya, Y., Kotoh, S. et al. (2002) Low vertebral can-
cellous bone density in peripubertal girls with Turner’s syndrome
and boys with hypogonadism. Journal of Pediatric Endocrinology
and Metabolism, 15, 1537–1542.
8 Bechtold, S., Rauch, F., Noelle, V. et al. (2001) Musculoskeletal
analyses of the forearm in young women with Turner syndrome: a
study using peripheral quantitative computed tomography. Journal
of Clinical Endocrinology &Metabolism, 86, 5819–5823.
9 Holroyd, C.R., Davies, J.H., Taylor, P. et al. (2010) Reduced corti-
cal bone density with normal trabecular bone density in girls with
Turner syndrome. Osteoporosis International, 21, 2093–2099.
10 Saenger, P., Wikland, K.A., Conway, G.S. et al. (2001) Recommen-
dations for the diagnosis and management of Turner syndrome.
Journal of Clinical Endocrinology &Metabolism, 86, 3061–3069.
11 van Pareren, Y.K., de Muinck Keizer-Schrama, S.M., Stijnen, T.
et al. (2003) Final height in girls with turner syndrome after long-
term growth hormone treatment in three dosages and low dose
estrogens. Journal of Clinical Endocrinology & Metabolism, 88,
1119–1125.
12 Rosenfield, R.L., Devine, N., Hunold, J.J. et al. (2005) Salutary
effects of combining early very low-dose systemic estradiol with
Bone mineral density in Turner syndrome 451
 2011 Blackwell Publishing Ltd, Clinical Endocrinology, 74, 445–452
growth hormone therapy in girls with Turner syndrome. Journal of
Clinical Endocrinology &Metabolism, 90, 6424–6430.
13 Kobzova, J., Vignerova, J., Blaha, P. et al. (2004) The 6th nation-
wide anthropological survey of children and adolescents in the
Czech Republic in 2001. Central European Journal of Public Health,
12, 126–130.
14 Rauch, F., Neu, C., Manz, F. et al. (2001) The development of
metaphyseal cortex–implications for distal radius fractures during
growth. Journal of Bone and Mineral Research, 16, 1547–1555.
15 Rauch, F. & Schoenau, E. (2005) Peripheral quantitative computed
tomography of the distal radius in young subjects - new reference
data and interpretation of results. Journal of Musculoskeletal and
Neuronal Interactions, 5, 119–126.
16 Rauch, F. & Schoenau, E. (2008) Peripheral quantitative computed
tomography of the proximal radius in young subjects–new refer-
ence data and interpretation of results. Journal of Musculoskeletal
and Neuronal Interactions, 8, 217–226.
17 Neu, C.M., Rauch, F., Manz, F. et al. (2001) Modeling of cross-
sectional bone size, mass and geometry at the proximal radius:
a study of normal bone development using peripheral quantita-
tive computed tomography. Osteoporosis International, 12, 538–
547.
18 Cole, T.J. (1990) The LMS method for constructing normalized
growth standards. European Journal of Clinical Nutrition, 44, 45–
60.
19 Gordon, C.M., Bachrach, L.K., Carpenter, T.O. et al. (2008) Dual
energy X-ray absorptiometry interpretation and reporting in chil-
dren and adolescents: the 2007 ISCD Pediatric Official Positions.
Journal of Clinical Densitometry, 11, 43–58.
20 Team, R.D.C. (2009) R: A Language and Environment for Statistical
Computing. R Foundation for Statistical Computing, Vienna, Aus-
tria.
21 Schoenau, E., Neu, C.M., Rauch, F. et al. (2002) Gender-specific
pubertal changes in volumetric cortical bone mineral density at the
proximal radius. Bone, 31, 110–113.
22 Frost, H.M. (1998) From Wolff’s law to the mechanostat: a
new ‘‘face’’ of physiology. Journal of Orthopaedic Science, 3,
282–286.
23 Seeman, E. (2008) Bone quality: the material and structural basis of
bone strength. Journal of Bone and Mineral Metabolism, 26, 1–8.
24 Wang, Q., Alen, M., Nicholson, P.H. et al. (2006) Differential
effects of sex hormones on peri- and endocortical bone surfaces in
pubertal girls. Journal of Clinical Endocrinology & Metabolism, 91,
277–282.
25 Bakalov, V.K., Axelrod, L., Baron, J. et al. (2003) Selective reduc-
tion in cortical bone mineral density in turner syndrome indepen-
dent of ovarian hormone deficiency. Journal of Clinical
Endocrinology &Metabolism, 88, 5717–5722.
26 Rittweger, J., Michaelis, I., Giehl, M. et al. (2004) Adjusting for the
partial volume effect in cortical bone analyses of pQCT images.
Journal of Musculoskeletal and Neuronal Interactions, 4, 436–441.
27 Ross, J.L., Long, L.M., Feuillan, P. et al. (1991) Normal bone den-
sity of the wrist and spine and increased wrist fractures in girls with
Turner’s syndrome. Journal of Clinical Endocrinology & Metabo-
lism, 73, 355–359.
28 Shaw, N.J., Rehan, V.K., Husain, S. et al. (1997) Bone mineral den-
sity in Turner’s syndrome–a longitudinal study. Clinical Endocri-
nology, 47, 367–370.
29 Sass, T.C., De Muinck Keizer-Schrama, S.M., Stijnen, T. et al.
(2000) A longitudinal study on bone mineral density until adult-
hood in girls with Turner’s syndrome participating in a growth
hormone injection frequency-response trial. Clinical Endocrinology,
52, 531–536.
30 Bakalov, V.K., Van, P.L., Baron, J. et al. (2004) Growth hormone
therapy and bone mineral density in Turner syndrome. Journal of
Clinical Endocrinology &Metabolism, 89, 4886–4889.
31 Ari, M., Bakalov, V.K., Hill, S. et al. (2006) The effects of growth
hormone treatment on bone mineral density and body composi-
tion in girls with turner syndrome. Journal of Clinical Endocrinology
&Metabolism, 91, 4302–4305.
32 Andreassen, T.T. & Oxlund, H. (2001) The effects of growth hor-
mone on cortical and cancellous bone. Journal of Musculoskeletal
and Neuronal Interactions, 2, 49–58.
33 Ueland, T., Ebbesen, E.N., Thomsen, J.S. et al. (2002) Decreased
trabecular bone biomechanical competence, apparent density, IGF-
II and IGFBP-5 content in acromegaly. European Journal of Clinical
Investigation, 32, 122–128.
34 Landin-Wilhelmsen, K., Nilsson, A., Bosaeus, I. et al. (2003)
Growth hormone increases bone mineral content in postmeno-
pausal osteoporosis: a randomized placebo-controlled trial. Journal
of Bone and Mineral Research, 18, 393–405.
35 Kalu, D.N., Banu, J. & Wang, L. (2000) How cancellous and cortical
bones adapt to loading and growth hormone. Journal of Musculo-
skeletal and Neuronal Interactions, 1, 19–23.
36 van Teunenbroek, A., Mulder, P., de Muinck Keizer-Schrama, S.
et al. (1995) Radiographic absorptiometry of the phalanges in
healthy children and in girls with Turner syndrome. Bone, 17, 71–
78.
452 O. Soucek et al.
 2011 Blackwell Publishing Ltd, Clinical Endocrinology, 74, 445–452
